192 related articles for article (PubMed ID: 26744530)
1. IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis.
Brooks GD; McLeod L; Alhayyani S; Miller A; Russell PA; Ferlin W; Rose-John S; Ruwanpura S; Jenkins BJ
Cancer Res; 2016 Feb; 76(4):866-76. PubMed ID: 26744530
[TBL] [Abstract][Full Text] [Related]
2. Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.
Miller A; McLeod L; Alhayyani S; Szczepny A; Watkins DN; Chen W; Enriori P; Ferlin W; Ruwanpura S; Jenkins BJ
Oncogene; 2017 May; 36(21):3059-3066. PubMed ID: 27893707
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
Green S; Trejo CL; McMahon M
Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
[TBL] [Abstract][Full Text] [Related]
4. IL22 Promotes
Khosravi N; Caetano MS; Cumpian AM; Unver N; De la Garza Ramos C; Noble O; Daliri S; Hernandez BJ; Gutierrez BA; Evans SE; Hanash S; Alekseev AM; Yang Y; Chang SH; Nurieva R; Kadara H; Chen J; Ostrin EJ; Moghaddam SJ
Cancer Immunol Res; 2018 Jul; 6(7):788-797. PubMed ID: 29764837
[TBL] [Abstract][Full Text] [Related]
5. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
[TBL] [Abstract][Full Text] [Related]
6. IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.
Caetano MS; Zhang H; Cumpian AM; Gong L; Unver N; Ostrin EJ; Daliri S; Chang SH; Ochoa CE; Hanash S; Behrens C; Wistuba II; Sternberg C; Kadara H; Ferreira CG; Watowich SS; Moghaddam SJ
Cancer Res; 2016 Jun; 76(11):3189-99. PubMed ID: 27197187
[TBL] [Abstract][Full Text] [Related]
7. NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.
Okayama H; Saito M; Oue N; Weiss JM; Stauffer J; Takenoshita S; Wiltrout RH; Hussain SP; Harris CC
Int J Cancer; 2013 Jan; 132(1):9-18. PubMed ID: 22618808
[TBL] [Abstract][Full Text] [Related]
8. Stomach-Specific Activation of Oncogenic KRAS and STAT3-Dependent Inflammation Cooperatively Promote Gastric Tumorigenesis in a Preclinical Model.
Thiem S; Eissmann MF; Elzer J; Jonas A; Putoczki TL; Poh A; Nguyen P; Preaudet A; Flanagan D; Vincan E; Waring P; Buchert M; Jarnicki A; Ernst M
Cancer Res; 2016 Apr; 76(8):2277-87. PubMed ID: 26837764
[TBL] [Abstract][Full Text] [Related]
9. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.
Cho HC; Lai CY; Shao LE; Yu J
Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965
[TBL] [Abstract][Full Text] [Related]
10. ETS1 regulates Twist1 transcription in a Kras
Millien G; Cao Y; O'Hara CJ; Tagne JB; Hinds A; Williams MC; Ramirez MI; Kathuria H
Clin Exp Metastasis; 2018 Mar; 35(3):149-165. PubMed ID: 29909489
[TBL] [Abstract][Full Text] [Related]
11. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
12. Mig-6 deficiency cooperates with oncogenic Kras to promote mouse lung tumorigenesis.
Liu J; Cho SN; Wu SP; Jin N; Moghaddam SJ; Gilbert JL; Wistuba I; DeMayo FJ
Lung Cancer; 2017 Oct; 112():47-56. PubMed ID: 29191600
[TBL] [Abstract][Full Text] [Related]
13. Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis.
Best SA; Vandenberg CJ; Abad E; Whitehead L; Guiu L; Ding S; Brennan MS; Strasser A; Herold MJ; Sutherland KD; Janic A
Cell Death Dis; 2020 Oct; 11(10):877. PubMed ID: 33082333
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 Prevents the Initiation but Enhances the Progression of Lung Cancer.
Qu Z; Sun F; Zhou J; Li L; Shapiro SD; Xiao G
Cancer Res; 2015 Aug; 75(16):3209-15. PubMed ID: 26122841
[TBL] [Abstract][Full Text] [Related]
15. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis.
Grabner B; Schramek D; Mueller KM; Moll HP; Svinka J; Hoffmann T; Bauer E; Blaas L; Hruschka N; Zboray K; Stiedl P; Nivarthi H; Bogner E; Gruber W; Mohr T; Zwick RH; Kenner L; Poli V; Aberger F; Stoiber D; Egger G; Esterbauer H; Zuber J; Moriggl R; Eferl R; Győrffy B; Penninger JM; Popper H; Casanova E
Nat Commun; 2015 Mar; 6():6285. PubMed ID: 25734337
[TBL] [Abstract][Full Text] [Related]
16. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.
Elsum IA; Yates LL; Pearson HB; Phesse TJ; Long F; O'Donoghue R; Ernst M; Cullinane C; Humbert PO
Oncogene; 2014 Nov; 33(48):5523-33. PubMed ID: 24276238
[TBL] [Abstract][Full Text] [Related]
17. ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.
Saad MI; Alhayyani S; McLeod L; Yu L; Alanazi M; Deswaerte V; Tang K; Jarde T; Smith JA; Prodanovic Z; Tate MD; Balic JJ; Watkins DN; Cain JE; Bozinovski S; Algar E; Kohmoto T; Ebi H; Ferlin W; Garbers C; Ruwanpura S; Sagi I; Rose-John S; Jenkins BJ
EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30833304
[TBL] [Abstract][Full Text] [Related]
18. Modulation of Mutant
Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA
Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919
[TBL] [Abstract][Full Text] [Related]
19. IL-6/Stat3-driven pulmonary inflammation, but not emphysema, is dependent on interleukin-17A in mice.
Ruwanpura SM; McLeod L; Brooks GD; Bozinovski S; Vlahos R; Longano A; Bardin PG; Anderson GP; Jenkins BJ
Respirology; 2014 Apr; 19(3):419-27. PubMed ID: 24506702
[TBL] [Abstract][Full Text] [Related]
20. STAT3 is Activated by CTGF-mediated Tumor-stroma Cross Talk to Promote HCC Progression.
Makino Y; Hikita H; Kato S; Sugiyama M; Shigekawa M; Sakamoto T; Sasaki Y; Murai K; Sakane S; Kodama T; Sakamori R; Kobayashi S; Eguchi H; Takemura N; Kokudo N; Yokoi H; Mukoyama M; Tatsumi T; Takehara T
Cell Mol Gastroenterol Hepatol; 2023; 15(1):99-119. PubMed ID: 36210625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
